Compare Ascendis Pharma A/S (ASND) vs D R Horton Inc (DHI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs D R Horton Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while D R Horton Inc trades at $151.2 (market cap $42.98B). The key difference: D R Horton Inc is far larger — about 2.4× Ascendis Pharma A/S's market cap, and D R Horton Inc pays a 1.19% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DHI | |
|---|---|---|
Market Cap | $17.74B | $42.98B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $184.04 |
52-Week Low | $163.32 | $129.82 |
Enterprise Value | $18.11B | $47.70B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
D.R. Horton (DHI) trades at $151.58, up 1.36% with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with declining revenue ($34.25B in 2025) and net income margins (9.51%), though valuation metrics remain reasonable (P/E 14.23). Analyst consensus leans neutral with a $163.13 price target, while cash flow trends show volatility with a $1.51B net outflow in 2025.
The housing market headwinds and cyclical nature of homebuilding present near-term risks, but DHI's scale and operational efficiency offer stability. With the stock trading below consensus targets and showing technical support at $145, value-oriented investors may find opportunity amid sector challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
